Examining the global antihypertensive medicine sales by country based on 2023 data, Austria leads with $7.6 PPP per capita, followed by Germany at $4.8, and Greece and Slovenia both at $4.2. Latvia stands at $2.8, Finland at $2.2, Norway at $2.1, and Estonia at $1.8. Lower on the scale, Luxembourg is at $1.3, South Korea at $1.1, and Chile at $0.8. Year-on-year variations in 2023 display diverse trends, with notable increases in Finland (7.96%) and Slovenia (6.96%), while Latvia and Germany showed declines of -7.34% and -1.59%, respectively.
Over the last five years, compound annual growth rates suggest moderate growth in some regions, hinting at stable demand, while countries like South Korea and Finland indicate newer upward trends. Future trends to watch include potential growth in Asian markets, driven by increasing healthcare awareness and aging populations, and continuous growth in European countries with higher health expenditures.
Top countries in Antihypertensive Medicine Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Austria | 7.6 | 2023 | +1.33% | +2.55% | View data |
| 2 | 2 Germany | 4.8 | 2023 | -2.04% | -1.59% | View data |
| 3 | 3 Greece | 4.2 | 2023 | 0% | +0.48% | View data |
| 4 | 4 Slovenia | 4.2 | 2023 | 0% | +6.96% | View data |
| 5 | 5 Latvia | 2.8 | 2023 | -9.68% | -7.34% | View data |
| 6 | 6 Finland | 2.2 | 2023 | +4.76% | +7.96% | View data |
| 7 | 7 Norway | 2.1 | 2023 | 0% | +0.98% | View data |
| 8 | 8 Estonia | 1.8 | 2023 | +5.88% | +5.15% | View data |
| 9 | 9 Luxembourg | 1.3 | 2023 | 0% | +5.39% | View data |
| 10 | 10 South Korea | 1.1 | 2023 | 0% | +6.58% | View data |
